Top Markets
#1 Glidr Glidr +51.75%
#2 DOVU DOVU +48.17%
#3 Velvet Velvet +37.34%
#4 Black Phoenix Black Phoenix +34.06%
#5 Akedo Akedo +29.10%
#6 Cross Cross +27.01%
#7 Cap Cap +18.79%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.46%
#9 QANplatform QANplatform +14.35%
#10 Bitway Bitway +13.02%
Coin of the day
Glidr Glidr
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
AIM ImmunoTech Inc. AIM ImmunoTech Inc.

AIM ImmunoTech Inc.

AIM
Classificação em ações #38741
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida,... AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Preço da ação
$0.2442
Valor de mercado
$831.14K
Variação (1 dia)
-5.46%
Variação (1 ano)
-89.91%
País
US
Negociar AIM ImmunoTech Inc. (AIM)

Categoria

Healthcare
Receita da AIM ImmunoTech Inc. (AIM)
Receita em Aug 2026 TTM: 0
De acordo com os últimos relatórios financeiros da AIM ImmunoTech Inc., a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da AIM ImmunoTech Inc. de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE